KR100543845B1 - 클로로푸린 중간체의 합성 방법 - Google Patents
클로로푸린 중간체의 합성 방법 Download PDFInfo
- Publication number
- KR100543845B1 KR100543845B1 KR1020007003921A KR20007003921A KR100543845B1 KR 100543845 B1 KR100543845 B1 KR 100543845B1 KR 1020007003921 A KR1020007003921 A KR 1020007003921A KR 20007003921 A KR20007003921 A KR 20007003921A KR 100543845 B1 KR100543845 B1 KR 100543845B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- acid
- ims
- carried out
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 239000000543 intermediate Substances 0.000 title abstract description 11
- JBMBVWROWJGFMG-UHFFFAOYSA-N 2-chloro-7h-purine Chemical compound ClC1=NC=C2NC=NC2=N1 JBMBVWROWJGFMG-UHFFFAOYSA-N 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 239000002253 acid Substances 0.000 claims abstract description 10
- 230000007062 hydrolysis Effects 0.000 claims abstract description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 7
- 238000011065 in-situ storage Methods 0.000 claims abstract description 7
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 6
- 125000006239 protecting group Chemical group 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 6
- -1 alkali metal bicarbonate Chemical class 0.000 claims description 5
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 239000011928 denatured alcohol Substances 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 239000003125 aqueous solvent Substances 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 238000006482 condensation reaction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 2
- 150000004292 cyclic ethers Chemical class 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000005270 trialkylamine group Chemical group 0.000 claims description 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 238000009833 condensation Methods 0.000 abstract description 2
- 230000005494 condensation Effects 0.000 abstract description 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 abstract 2
- 239000002212 purine nucleoside Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 5
- 229960004748 abacavir Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- XYWHZUCZNRMJGO-UHFFFAOYSA-N n-(2-amino-4,6-dichloropyrimidin-5-yl)formamide Chemical compound NC1=NC(Cl)=C(NC=O)C(Cl)=N1 XYWHZUCZNRMJGO-UHFFFAOYSA-N 0.000 description 3
- HWSJQFCTYLBBOF-UHFFFAOYSA-N 2,5-diamino-4-hydroxy-1h-pyrimidin-6-one Chemical compound NC1=NC(O)=C(N)C(O)=N1 HWSJQFCTYLBBOF-UHFFFAOYSA-N 0.000 description 2
- 150000005019 2-aminopurines Chemical class 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- ZXWGHENZKVQKPX-UHFFFAOYSA-N 4,6-dichloropyrimidine-2,5-diamine Chemical compound NC1=NC(Cl)=C(N)C(Cl)=N1 ZXWGHENZKVQKPX-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001480079 Corymbia calophylla Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- UXKZFJDNFBNQHE-RITPCOANSA-N N[C@H]1C=C[C@@H](CO)C1 Chemical compound N[C@H]1C=C[C@@H](CO)C1 UXKZFJDNFBNQHE-RITPCOANSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (14)
- 하기 화학식 IV의 화합물을 산의 존재하에 가수분해시키는 단계,형성된 하기 화학식 V의 생성물을 극성 용매 중에서 염기의 존재하에 동일반응계에서 하기 화학식 VI의 화합물과 축합시키는 단계, 이어서얻어진 하기 화학식 VII의 중간체를 동일반응계에서 폐환 반응시켜 하기 화학식 I의 화합물 (이 화학식 I의 화합물은 임의로 산과 반응하여 그의 염을 형성할 수 있다)을 형성하는 단계를 포함하는(comprising), 임의로 염 형태인 하기 화학식 I의 화합물의 제조 방법.<화학식 I><화학식 IV><화학식 V><화학식 VI><화학식 VII>상기 각 식에서,P는 보호기이고,R은 CHO 또는 H를 나타낸다.
- 제1항에 있어서, R이 CHO인 방법.
- 제1항 또는 제2항에 있어서, P가 아실 또는 치환된 옥시카르보닐기인 방법.
- 제3항에 있어서, P가 포르밀, C1-C4 알카노일기 또는 화학식 R'OC(O) (여기서, R'는 알킬 또는 아르알킬임)의 옥시카르보닐기인 방법.
- 제4항에 있어서, P가 아세틸기이거나 또는 R'가 tert-부틸 또는 벤질인 방법.
- 제1항 또는 제2항에 있어서, 가수분해 단계가 유기산 또는 무기산의 존재하에 알칸올, 시클릭 에테르, 또는 염소화 탄화수소 중에서 수행되는 방법.
- 제6항에 있어서, 가수분해 단계가 IMS (공업적 메틸화 주정: industrial methylated spirit) 중에서 수행되고, 산이 트리플루오로아세트산 또는 염산인 방법.
- 제1항 또는 제2항에 있어서, 축합 반응이 환류하에서 수행되는 방법.
- 제8항에 있어서, 극성 용매가 알코올, 물 또는 아세토니트릴이고, 염기가 트리알킬아민, 알칼리 금속 탄산염, 또는 알칼리 금속 중탄산염인 방법.
- 제9항에 있어서, 염기가 탄산칼륨, 탄산나트륨, 또는 중탄산나트륨인 방법.
- 제1항 또는 제2항에 있어서, 폐환 반응이 무기산 및 임의로 1종 이상의 비수성 용매의 존재하에 트리알킬오르토포르메이트를 사용하여 수행되는 방법.
- 제11항에 있어서, 폐환 반응이 염산의 존재하에 트리에틸오르토포르메이트를 사용하여 수행되는 방법.
- 제11항에 있어서, 비수성 용매가 테트라히드로푸란, 에틸 아세테이트 또는 IMS인 방법.
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9721780.6 | 1997-10-14 | ||
GBGB9721780.6A GB9721780D0 (en) | 1997-10-14 | 1997-10-14 | Process for the synthesis of chloropurine intermediates |
PCT/GB1998/003080 WO1999019327A1 (en) | 1997-10-14 | 1998-10-14 | Process for the synthesis of chloropurine intermediates |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010015744A KR20010015744A (ko) | 2001-02-26 |
KR100543845B1 true KR100543845B1 (ko) | 2006-01-23 |
Family
ID=10820547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007003921A KR100543845B1 (ko) | 1997-10-14 | 1998-10-14 | 클로로푸린 중간체의 합성 방법 |
Country Status (44)
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SK284596B6 (sk) | 1997-11-27 | 2005-07-01 | Lonza Ag | Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purin-9-yl)-2-cyklopentén-1-metanolu alebo jeho solí |
FR2849030A1 (fr) * | 2002-12-20 | 2004-06-25 | Isochem Sa | Procede de preparation des n-(2-amino-4, 6-dihalogenopyrimidin-5-yl) formamides |
GB0320738D0 (en) | 2003-09-04 | 2003-10-08 | Glaxo Group Ltd | Novel process |
CN100465174C (zh) * | 2006-06-13 | 2009-03-04 | 中国科学院上海有机化学研究所 | 制备光学纯阿巴卡韦的方法 |
KR101109476B1 (ko) * | 2009-06-26 | 2012-01-31 | 현대제철 주식회사 | 실린더 교체용 지그장치 |
NZ627826A (en) | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
CN104672239A (zh) * | 2013-11-26 | 2015-06-03 | 上海迪赛诺化学制药有限公司 | 一种采用一锅法制备阿巴卡韦式v中间体的工艺 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021161A1 (en) * | 1994-02-04 | 1995-08-10 | The Wellcome Foundation Limited | Chloropyrimide intermediates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4268672A (en) * | 1977-02-09 | 1981-05-19 | The Regents Of The University Of Minnesota | Adenosine deaminase resistant antiviral purine nucleosides and method of preparation |
JPS6175A (ja) * | 1984-03-06 | 1986-01-06 | ブリストル−マイア−ズ コムパニ− | 神経弛緩剤、1‐フルオロフェニルブチル‐4‐(5‐ハロ‐2‐ピリミジニル)ピペラジン誘導体 |
US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
IT1229531B (it) * | 1988-01-20 | 1991-09-04 | Univ Minnesota | Composti nucleosidi dideossidideidrocarbociclici e formulazione farmaceutica che li contiene |
NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
MY104575A (en) | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
US5126452A (en) * | 1990-04-06 | 1992-06-30 | Glaxo Inc. | Synthesis of purine substituted cyclopentene derivatives |
US5329008A (en) * | 1993-04-07 | 1994-07-12 | Glaxo Inc. | Synthesis of a 3,4-dihydroxy-1-cyclopentanylpurinone |
SK285228B6 (sk) * | 1997-05-13 | 2006-09-07 | Lonza Ag | Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén |
-
1997
- 1997-10-14 GB GBGB9721780.6A patent/GB9721780D0/en not_active Ceased
-
1998
- 1998-10-12 PE PE1998000960A patent/PE121899A1/es not_active IP Right Cessation
- 1998-10-13 MY MYPI98004673A patent/MY127470A/en unknown
- 1998-10-13 EG EG124098A patent/EG21730A/xx active
- 1998-10-13 IN IN1821CA1998 patent/IN184590B/en unknown
- 1998-10-13 CO CO98059323A patent/CO4980899A1/es unknown
- 1998-10-13 AR ARP980105097A patent/AR014921A1/es active IP Right Grant
- 1998-10-13 MA MA25292A patent/MA24676A1/fr unknown
- 1998-10-13 ZA ZA9809338A patent/ZA989338B/xx unknown
- 1998-10-14 ID IDW20000707A patent/ID24927A/id unknown
- 1998-10-14 EP EP98949093A patent/EP1023292B1/en not_active Expired - Lifetime
- 1998-10-14 RS YUP-202/00A patent/RS49710B/sr unknown
- 1998-10-14 ES ES98949093T patent/ES2205553T3/es not_active Expired - Lifetime
- 1998-10-14 CA CA002306958A patent/CA2306958C/en not_active Expired - Lifetime
- 1998-10-14 GE GEAP19985300A patent/GEP20022679B/en unknown
- 1998-10-14 CZ CZ20001367A patent/CZ294482B6/cs not_active IP Right Cessation
- 1998-10-14 BR BRPI9813048-0A patent/BR9813048B1/pt not_active IP Right Cessation
- 1998-10-14 TR TR2000/00976T patent/TR200000976T2/xx unknown
- 1998-10-14 DE DE69818084T patent/DE69818084T2/de not_active Expired - Lifetime
- 1998-10-14 CN CNB988121522A patent/CN1160354C/zh not_active Expired - Lifetime
- 1998-10-14 PL PL98339904A patent/PL188477B1/pl unknown
- 1998-10-14 IL IL13532398A patent/IL135323A/en not_active IP Right Cessation
- 1998-10-14 UA UA2000031789A patent/UA54550C2/uk unknown
- 1998-10-14 DK DK98949093T patent/DK1023292T3/da active
- 1998-10-14 HU HU0003984A patent/HUP0003984A3/hu unknown
- 1998-10-14 AP APAP/P/2000/001790A patent/AP1182A/en active
- 1998-10-14 TW TW087117057A patent/TW436488B/zh not_active IP Right Cessation
- 1998-10-14 EE EEP200000162A patent/EE04059B1/xx unknown
- 1998-10-14 KR KR1020007003921A patent/KR100543845B1/ko not_active IP Right Cessation
- 1998-10-14 NZ NZ503679A patent/NZ503679A/xx not_active IP Right Cessation
- 1998-10-14 US US09/529,385 patent/US6646125B1/en not_active Expired - Lifetime
- 1998-10-14 AU AU95476/98A patent/AU738462B2/en not_active Expired
- 1998-10-14 JP JP2000515898A patent/JP4531250B2/ja not_active Expired - Lifetime
- 1998-10-14 AT AT98949093T patent/ATE249461T1/de active
- 1998-10-14 SK SK536-2000A patent/SK285331B6/sk not_active IP Right Cessation
- 1998-10-14 PT PT98949093T patent/PT1023292E/pt unknown
- 1998-10-14 EA EA200000318A patent/EA003183B1/ru not_active IP Right Cessation
- 1998-10-14 WO PCT/GB1998/003080 patent/WO1999019327A1/en active IP Right Grant
-
2000
- 2000-03-28 IS IS5423A patent/IS2195B/is unknown
- 2000-04-07 OA OA1200000101A patent/OA11370A/en unknown
- 2000-04-12 NO NO20001896A patent/NO325030B1/no not_active IP Right Cessation
- 2000-04-14 HR HR980147A patent/HRP20000216B1/xx not_active IP Right Cessation
- 2000-04-18 BG BG104352A patent/BG64597B1/bg unknown
- 2000-11-02 HK HK00106983A patent/HK1027807A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995021161A1 (en) * | 1994-02-04 | 1995-08-10 | The Wellcome Foundation Limited | Chloropyrimide intermediates |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6870053B2 (en) | Chloropyrimidine intermediates | |
MXPA96003091A (en) | Cloropirimid intermediaries | |
JPS58172367A (ja) | 二環式アミノ酸の新規な誘導体 | |
JPH0841061A (ja) | 2−(2−アミノ−1,6−ジヒドロ−6−オキソ−プリン−9−イル)メトキシ−1,3−プロパンジオール誘導体 | |
KR100543845B1 (ko) | 클로로푸린 중간체의 합성 방법 | |
MXPA00003379A (en) | Process for the synthesis of chloropurine intermediates | |
CA2182105C (en) | Chloropyrimide intermediates | |
RU2190597C2 (ru) | Способ получения антагонистов nmda (n-метил-d-аспартата) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121227 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131227 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 13 |
|
EXPY | Expiration of term |